<DOC>
	<DOCNO>NCT01357915</DOCNO>
	<brief_summary>The purpose study evaluate persistence vaccine induce immune response Month 48 ( Year 4 ) Month 60 ( Year 5 ) healthy subject receive 3 dos GSK Biologicals ' candidate CMV vaccine accord 0-1-6 month schedule primary study 108890 ( NCT00435396 ) ( vaccine group ) . The immune response CMV infection naturally infected subject participate screen visit primary study 108890 ( NCT00435396 ) test CMV-seropositive , use reference value ( seropositive reference group ) . In addition , study continue assess occurrence CMV infection well continue development validation read-out CMV project . The primary vaccination phase Year 2 follow-up post separate protocol posting ( NCT00435396 ) .</brief_summary>
	<brief_title>Evaluation Long-term Persistence GlaxoSmithKline ( GSK ) Biologicals ' Candidate Cytomegalovirus ( CMV ) Vaccine</brief_title>
	<detailed_description>During long-term follow-up study , subject receive 3 dos GSK Biologicals ' candidate CMV vaccine accord 0-1-6 month schedule primary study 108890 ( NCT00435396 ) invite participate Visit 8 ( Year 4 ) Visit 9 ( Year 5 ) vaccine group . In addition , healthy subject participate screen visit primary study 108890 ( NCT00435396 ) test CMV-seropositive invited Visit 9 ( Year 5 ) study seropositive reference group.This Protocol Posting update follow Protocol Amendment 1 , March 2012 , lead update brief summary , intervention model , enrolment , outcome measure , eligibility arm .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g. , return followup visit ) enrol study . Written inform consent obtain subject . Healthy subject establish clinical evaluation ( medical history physical examination ) enter study . Subjects vaccine group addition satisfy follow criterion : • Subjects participate primary study 108890 ( NCT00435396 ) , receive 3 dos GSK 's CMV candidate vaccine complete Year 2 followup study 109211 ( NCT00435396 ) . Subjects seropositive reference group addition satisfy follow criterion : • Subjects participate screen visit primary study 108890 ( NCT00435396 ) , whose blood sample take visit test CMV positive . Use , plan use , investigational nonregistered product ( drug vaccine ) study period . Chronic administration immunosuppressant immunemodifying drug within six month prior study visit ( ) . For corticosteroid , mean prednisone , 20mg/day , equivalent . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product within three month precede study visit ( ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . For subject vaccine group , follow exclusion criterion check addition : • Administration additional CMV vaccine since end primary study 108890 ( NCT00435396 ) . For subject seropositive reference group , follow exclusion criterion check addition : • Administration CMV vaccine since screen visit primary study 108890 ( NCT00435396 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Vaccine</keyword>
</DOC>